- Newly diagnosed patients with metastatic cervical cancer treated with definitive pelvic radiotherapy+chemotherapy (CRT) showed significant improvement in OS compared with chemotherapy alone.
- Radiation dose ≥45 Gy, external beam radiation therapy (EBRT)+brachytherapy, and concurrent CRT improved OS.
Why this matters
- Definitive pelvic CRT is the standard of care for locally advanced cervical cancer, but the evidence supporting its role in metastatic disease is limited.
- Study of 3169 patients with newly diagnosed metastatic cervical cancer from National Cancer Database who received chemotherapy ± radiation therapy during 2004-2014.
- Funding: None disclosed.
- 808 patients received chemotherapy alone and 2361 were treated with pelvic CRT.
- Median follow-up, 13.3 months.
- Median OS improved significantly in patients who received CRT vs chemotherapy alone (15.6 vs 10.1 months; HR, 0.72; P<.001>
- Propensity score-matched analysis showed superior median survival with CRT vs chemotherapy alone (14.4 vs 10.6 months; P<.001>
- Median OS was longer in patients who received:
- radiation therapy with a dose ≥45 vs
- EBRT+brachytherapy+chemotherapy vs EBRT+chemotherapy (27.5 vs 12.9 months; HR [vs chemotherapy alone], 0.50; P<.001 and>
- concurrent vs nonconcurrent chemoradiation (16.4 vs 14.3 months).
- Retrospective design.